SUPRANE Drug Patent Profile
✉ Email this page to a colleague
When do Suprane patents expire, and when can generic versions of Suprane launch?
Suprane is a drug marketed by Baxter Hlthcare and is included in one NDA.
The generic ingredient in SUPRANE is desflurane. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the desflurane profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Suprane
A generic version of SUPRANE was approved as desflurane by SHANGHAI HENGRUI on February 26th, 2018.
Summary for SUPRANE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 55 |
| Clinical Trials: | 35 |
| Patent Applications: | 1,352 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SUPRANE |
| What excipients (inactive ingredients) are in SUPRANE? | SUPRANE excipients list |
| DailyMed Link: | SUPRANE at DailyMed |
Recent Clinical Trials for SUPRANE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute, Egypt | N/A |
| Sefako Makgatho Health Sciences University | N/A |
| GÜNER KAYA | N/A |
Pharmacology for SUPRANE
| Drug Class | General Anesthetic |
| Physiological Effect | General Anesthesia |
Anatomical Therapeutic Chemical (ATC) Classes for SUPRANE
Paragraph IV (Patent) Challenges for SUPRANE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SUPRANE | Inhalation | desflurane | 99.9% | 020118 | 1 | 2008-09-11 |
US Patents and Regulatory Information for SUPRANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | SUPRANE | desflurane | LIQUID;INHALATION | 020118-001 | Sep 18, 1992 | AN | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SUPRANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | SUPRANE | desflurane | LIQUID;INHALATION | 020118-001 | Sep 18, 1992 | ⤷ Try a Trial | ⤷ Try a Trial |
| Baxter Hlthcare | SUPRANE | desflurane | LIQUID;INHALATION | 020118-001 | Sep 18, 1992 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SUPRANE
See the table below for patents covering SUPRANE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 69224823 | ⤷ Try a Trial | |
| New Zealand | 223315 | ANAESTHETIC COMPOSITION CONTAINING 2-(DIFLUOROMETHOXY)-1,1,1,2-TETRAFLUOROETHANE | ⤷ Try a Trial |
| Austria | 164087 | ⤷ Try a Trial | |
| Finland | 933326 | ⤷ Try a Trial | |
| Australia | 658170 | ⤷ Try a Trial | |
| Germany | 3870959 | ⤷ Try a Trial | |
| Finland | 107997 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SUPRANE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0285237 | 94C0006 | France | ⤷ Try a Trial | PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505 |
| 0285237 | 95C0008 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
